Therapeutic approaches‐ aflibercept first french results of intravitreous aflibercept for active naïve polypoidal choroidal vasculopathy‐6 months follow up

Abstract

Listen

Translate article

AbstractTo evaluate the anatomical and functional effect of intravitreous aflibercept (IAI) for the treatment of polypoidal choroidal vasculopathy (PCV) associated with exudative AMD, with a follow up of 3 months.This is a case series study that included 22 eyes with active PCV. All eyes were naive to treatment before inclusion in the study. The treatment protocol consisted of an induction phase of 3 IAI, then the injections were done every 2 months. A complete ophthalmologic workup was done for every patient and included: best corrected visual acuity (ETDRS scale), Fluorescein and Indocyanine Green Angiography, EDI‐OCT (Spectralis HRA+OCT®, Heidelberg engineering). All results were analyzed at inclusion and at 3 months.The mean age was 76.3 +/‐ 11.3. Male to female ratio was 1. The BCVA improved at 3 months (0.58 +/‐ 0.39logMAR vs 0.20±0.27 log MAR; p= 0.01). The patients gained a mean of 15 letters in the BCVA. No loss of BCVA was noted in any patient. The central macular thickness improved significantly from 376.77+/‐99.54 to 279.80±82.53 at 3 months (p= 0.043).The polyp’s regression started at one month after the first injection and was almost complete at 3 months. A significant improvement of retinal pigment epithelium detachment